Amedeo Smart

Free Medical Literature Service



Alzheimer's Disease

  Free Subscription

Articles published in
    August 2021
  1. ILIFFE S, Manthorpe J
    Aducanumab, amyloid, and culture wars.
    BMJ. 2021;374:n2038.
    >> Share

    July 2021
  2. DYER O
    FDA calls for investigation into industry influence during Alzheimer's drug approval.
    BMJ. 2021;374:n1778.
    >> Share

  3. WALSH S, Merrick R, Milne R, Brayne C, et al
    Aducanumab for Alzheimer's disease?
    BMJ. 2021;374:n1682.
    >> Share

    June 2021
    Three FDA advisory panel members resign over approval of Alzheimer's drug.
    BMJ. 2021;373:n1503.
    >> Share

    FDA approves controversial Alzheimer's drug despite uncertainty over effectiveness.
    BMJ. 2021;373:n1462.
    >> Share

    February 2021
  6. ACKLEY SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, et al
    Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis.
    BMJ. 2021;372:n156.
    >> Share

    October 2020
  7. SHI J, Sabbagh MN, Vellas B
    Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.
    BMJ. 2020;371:m3684.
    >> Share

    December 2019
  8. JOE E, Ringman JM
    Cognitive symptoms of Alzheimer's disease: clinical management and prevention.
    BMJ. 2019;367:l6217.
    >> Share

    October 2019
    FDA considers Alzheimer's drug previously abandoned for lack of effectiveness.
    BMJ. 2019;367:l6164.
    >> Share

    March 2019
    Long term hormone therapy may increase Alzheimer's risk, study finds.
    BMJ. 2019;364:l1050.
    >> Share

  11. SAVOLAINEN-PELTONEN H, Rahkola-Soisalo P, Hoti F, Vattulainen P, et al
    Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study.
    BMJ. 2019;364:l665.
    >> Share

  12. MAKI PM, Girard LM, Manson JE
    Menopausal hormone therapy and cognition.
    BMJ. 2019;364:l877.
    >> Share

    September 2018
  13. BRAILLON A, Wilson M
    Does moderate alcohol consumption really have health benefits?
    BMJ. 2018;362:k3888.
    >> Share

    August 2018
  14. HAWKES N
    Alzheimer's disease: researcher behind "new test" paper tried to silence critics.
    BMJ. 2018;362:k3444.
    >> Share

    March 2018
  15. MAYOR S
    Alzheimer's disease research: five minutes with John Hardy.
    BMJ. 2018;360:k1163.
    >> Share

    January 2018
  16. HAWKES N
    Pfizer abandons research into Alzheimer's and Parkinson's diseases.
    BMJ. 2018;360:k122.
    >> Share

    December 2017
  17. LARSSON SC, Traylor M, Malik R, Dichgans M, et al
    Modifiable pathways in Alzheimer's disease: Mendelian randomisation analysis.
    BMJ. 2017;359:j5375.
    >> Share

  18. SOMMERLAD A, Livingston G
    Preventing Alzheimer's dementia.
    BMJ. 2017;359:j5667.
    >> Share

    June 2017

  19. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
    BMJ. 2017;357:j3170.
    >> Share

    Proton pump inhibitor use does not raise dementia and Alzheimer's risk, study suggests.
    BMJ. 2017;357:j3063.
    >> Share

    April 2017
  21. BENN M, Nordestgaard BG, Frikke-Schmidt R, Tybjaerg-Hansen A, et al
    Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
    BMJ. 2017;357:j1648.
    >> Share

  22. WISE J
    Vascular risk factors show link to development of Alzheimer's.
    BMJ. 2017;357:j1847.
    >> Share

    February 2017
  23. HAWKES N
    Merck ends trial of potential Alzheimer's drug verubecestat.
    BMJ. 2017;356:j845.
    >> Share

    December 2016
  24. LE COUTEUR DG, Hunter S, Brayne C
    Solanezumab and the amyloid hypothesis for Alzheimer's disease.
    BMJ. 2016;355:i6771.
    >> Share

  25. MAYOR S
    Statins are linked to reduced Alzheimer's risk, study finds.
    BMJ. 2016;355:i6675.
    >> Share

    November 2016
  26. HAWKES N
    Sixty seconds on . . . solanezumab.
    BMJ. 2016;355:i6389.
    >> Share

  27. HAWKES N
    Promise of new Alzheimer's drug is dashed after lack of evidence.
    BMJ. 2016;355:i6362.
    >> Share

    January 2016
    Approved drugs are to be studied for use in Alzheimer's disease.
    BMJ. 2016;354:i5063.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016